Want to join the conversation?
Medical device maker $EW reported a rise in 2Q16 earnings driven by significant growth in the number of patients and physicians choosing transcatheter heart valve therapy. Net income rose to $126.6MM or $0.58 per share from $112.7MM or $0.51 per share last year. Net sales grew 23.1% to $759.3MM. Adjusted EPS jumped 33% to $0.76.
$WBA is yet to receive US anti-trust clearance for its Rite Aid acquisition. The deadline for the deal expires on January 27.
$BMY plunge 7.2%. No credits to the non-acceleration of approval for lung cancer combination treatment.